Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812486 | 1.00 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| SCHEMBL16812355 | 0.94 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MEN1KMT2APDE2A | |
| SCHEMBL16812493 | 0.88 | NR3C1 (0.39) | SMN1; SMN2TP53ALDH1A1MEN1KMT2A | |
| SCHEMBL16812352 | 0.88 | PDE1B (0.38) | SMN1; SMN2HSD17B10ALDH1A1POLBMEN1 | |
| SCHEMBL16812354 | 0.88 | CDK5 (0.39) | NPC1RAB9ASMN1; SMN2TP53MEN1 | |
| SCHEMBL16794676 | 0.87 | PDE1B (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL18161034 | 0.85 | PDE1B (0.41) | SMN1; SMN2ALDH1A1MEN1KMT2APDE1B | |
| SCHEMBL24263381 | 0.84 | PDE1B (0.39) | SMN1; SMN2ALDH1A1MEN1KMT2APDE1B | |
| SCHEMBL16794653 | 0.84 | CNR2 (0.41) | ALDH1A1POLB | |
| SCHEMBL16794695 | 0.84 | TYK2 (0.44) | MEN1KMT2APDE2APDE1BNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | NPC1 4877/4885RAB9A 2405/4885SMN1; SMN2 4093/4885 |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | TYK2, IFNG, IFNAR1 | NPC1 4873/4885RAB9A 2273/4885SMN1; SMN2 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.